The Science Behind Dual Agonists The next generation of weight loss medications combines GLP-1 action with another hormone called GIP (glucose-dependent insulinotropic polypeptide)
Clinical trials have consistently shown that patients treated with semaglutide GLP-1 experience significant weight loss compared to those receiving a placebo, often exceeding the results achieved with other anti-obesity medications
Nausea, vomiting, and diarrhea are common, and depending on the person there are real risks of acute kidney injury, gallstones, and pancreatitis, plus muscle and bone loss in older adults
Watch our webinar, Emerging clinical applications for GLP-1 receptor agonists, to learn more
Itll change your life, just like it did mine! Chralotte Nguyen, Melbourne, Australia Ive struggled with insecurity and discomfort due to swollen lymph nodes on my neck for as long as I can remember, and its caused me a lot of distress in life
For many of my clients, this is the first time they have ever experienced a quiet brain
/assets/images/provider/photos/2826746.png)
